

## Certificate of Analysis

### FGFR3, active

(Recombinant enzyme expressed in SF21 insect cells)

Item # 14-464, 14-464-K, 14-464M

Parent Lot # 1832558

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

**Product Description:** N-terminal 6His-tagged, recombinant, human FGFR3, amino acids 447–761, expressed by baculovirus in SF21 insect cells. Purified using Ni<sup>2+</sup>/NTA-agarose. Purity 75.1% by SDS-PAGE and Coomassie blue staining. MW = 36.9kDa.

**Specific Activity (Parent lot# 1832558):** 2301U/mg, where one unit of FGFR3, active activity is defined as 1nmol phosphate incorporated into 0.1mg/ml poly(Glu, Tyr) (4:1) per minute at 30°C with a final ATP concentration of 100µM.

**Formulation:** 0.561mg/ml in 50mM Tris/HCl pH7.5, 150mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution.


**Storage and Stability:** On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

**Handling Recommendations:** Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY  
NOT FOR USE IN HUMANS OR ANIMALS**

### Quality Control Testing

**Kinase Assay:** 0.7–14.0ng of this lot of enzyme phosphorylated 0.1mg/ml poly(Glu, Tyr) (4:1) in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



**MS Tryptic Fingerprint:** Confirmed product identity as FGFR3 with the translated sequence listed on page three.



## Certificate of Analysis

### Kinase Assay Protocol

#### Stock Solutions:

1. **5 x Reaction Buffer:** 40mM MOPS/NaOH pH7.0, 1mM EDTA.
2. **Manganese Chloride (MnCl<sub>2</sub>):** Use at a final assay concentration of 10mM. Prepare a 200mM stock and add 1.25µl per assay point.
3. **Poly(Glu, Tyr) (4:1):** Use at a final assay concentration of 0.1mg/ml. Make up a 1mg/ml stock. Add 2.5µl of stock per assay point.
4. **FGFR3, active:** Dilute with 20mM MOPS/NaOH pH7.0, 1mM EDTA, 0.01% Brij-35, 5% glycerol, 0.1% 2-mercaptoethanol, 1mg/ml BSA. Use 0.7–14.0ng per assay point.
5. **[γ-<sup>33</sup>P]ATP:** 2.5 x magnesium acetate/[γ-<sup>33</sup>P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ-<sup>33</sup>P]ATP (specific activity approximately 500 - 800cpm/pmol as required.)

#### Assay Procedure (96 well plate format):

1. Add 5µl of 5 x reaction buffer per assay to wells.
2. Add 2.5µl of 1mg/ml **poly(Glu, Tyr) (4:1)**.
3. Add 1.25µl of MnCl<sub>2</sub>.
4. Add 3.75µl of dH<sub>2</sub>O.
5. Add **2.5µl (0.7–14.0ng) FGFR3, active**.
6. Add 10µl of diluted [γ-<sup>33</sup>P]ATP mixture.
7. Incubate for 10 minutes at 30°C.
8. Stop the reaction by adding 5µl of 3% phosphoric acid.
9. Transfer a 10µl aliquot onto the appropriate area of a **Filtermat A**.
10. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
11. Wash the filtermat once for 2 minutes with methanol.
12. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
13. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1µl of 30% phosphoric acid.

# Certificate of Analysis

## FGFR3 Sequence Information

<b><u>Protein</u></b>	Human FGFR3
<b><u>Tags</u></b>	N-terminal 6His
<b><u>Native sequence</u></b>	E10 of the recombinant protein is equivalent to E447 of human FGFR3
<b><u>Accession number</u></b>	GenBank M58051

### ***Recombinant FGFR3 amino acid sequence:***

```

1  MHHHHHHEFE  GPTLANVSEL  ELPADPKWEL  SRARLTGKLP  LGEGCFGQVV  MAEAIGIDKD
61  RAAKPVTAVAV  KMLKDDATDK  DLSDLVSEME  MMKMIGKHKH  IINLLGACTQ  GGPLYVLVEY
121 AAKGNLREFL  RARRPPGLDY  SFDCKPPEE  QLTFKDLVSC  AYQVARGMEY  LASQKCIHRD
181 LAARNVLVTE  DNMVKIADFG  LARDVHNLDY  YKKTNGRLP  VKWMAPEALF  DRVYTHQSDV
241 WSFGVLLWEI  FTLGGSPYPG  IPVEELFKLL  KEGHRMDKPA  NCTHDLYMIM  RECWAAPSQ
301 RPTFKQLVED  LDRVLTVTST  DEYL

```

### ***Recombinant FGFR3 nucleotide sequence:***

```

1  atgcatcatc  accatcacca  tgaattcgaa  ggccccacgc  tggccaatgt  ctccgagctc
61  gagctgcctg  cggaccccaa  atgggagctg  tctcgggccc  ggctgaccct  gggcaagccc
121 cttggggagg  gctgcttcgg  ccaggtaggtc  atggcggagg  ccatcggcat  tgacaaggac
181 cgggccgcca  agcctgtcac  cgtagccgtg  aagatgctga  aagacgatgc  cactgacaag
241 gacctgtcgg  acctggtgtc  tgagatggag  atgatgaaga  tgatcgggaa  acacaaaaac
301 atcatcaacc  tgcctggcgc  ctgcacgcag  ggcgggcccc  tgtacgtgct  ggtggagtac
361 gcggccaagg  gtaacctgcg  ggagtttctg  cgggcgcggc  ggcccccggg  cctggactac
421 tccttcgaca  cctgcaagcc  gcccgaggag  cagctcacct  tcaaggacct  ggtgtcctgt
481 gcctaccagg  tggcccgggg  catggagtac  ttggcctccc  agaagtgcac  ccacagggac
541 ctggctgccc  gcaatgtgct  ggtgaccgag  gacaacgtga  tgaagatcgc  agacttcggg
601 ctggcccggg  acgtgcacaa  cctcgactac  tacaagaaga  caaccaacgg  ccggctgccc
661 gtgaagtgga  tggcgcttga  ggccttgttt  gaccgagtct  aactcacca  gactgacgtc
721 tggtcctttg  gggtcctgct  ctgggagatc  ttcacgctgg  ggggctcccc  gtaccccggc
781 atccctgtgg  aggagctctt  caagctgctg  aaggagggcc  accgcatgga  caagcccgcc
841 aactgcacac  acgacctgta  catgatcatg  cgggagtgtc  ggcatgccgc  gccctccag
901 agggccacct  tcaagcagct  ggtggaggac  ctggaccgtg  tccttaccgt  gacgtccacc
961 gacgagtacc  tgtga

```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services.